Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8291288 | 0.99 | MAPT (0.63) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL26231994 | 0.90 | MAPT (0.53) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL25391627 | 0.89 | MAPT (0.52) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL8289588 | 0.88 | MAPT (0.51) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL26231989 | 0.86 | MAPT (0.58) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL25390693 | 0.84 | MAPT (0.48) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL25391245 | 0.83 | TSHR (0.53) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL25394642 | 0.82 | MAPT (0.47) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL25392218 | 0.82 | MAPT (0.48) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL8291320 | 0.82 | MAPT (0.67) | MAPTLMNANPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286955-A1 | INHIBITORS OF THEM1 | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2023-09-14 | — | — | US | disclosed |
| US-20230286955-A1 | INHIBITORS OF THEM1 | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2023-09-14 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2105441-A1 | Alanyl aminopeptidase and dipeptidylpeptidase IV dual inhibitors for the treatment of immunological, inflammatory, neuronal and other illnesses | IMTM GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| WO-2005034940-A2 | DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286955-A1 | INHIBITORS OF THEM1 | GOT1, GOT2, FAR1 | MAPT 4031/4885LMNA 1861/4885NPSR1 932/4885 |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | DNPEP, PREP, ANPEP | MAPT 1296/4885LMNA 3650/4885NPSR1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.